Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era.
Fatola A, Evans MD, Brown J, Davis E, Johnson A, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Eubanks S, Akwaa F, Clover T, Kreuziger LB, Sadler JE, Sridharan M, Go RS, McCrae KR, Upreti HV, Lim MY, Kocher NK, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Mazepa M, Chaturvedi S.
Fatola A, et al. Among authors: zheng xl.
Blood Adv. 2025 Jan 28;9(2):417-424. doi: 10.1182/bloodadvances.2024013313.
Blood Adv. 2025.
PMID: 39626301